Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea

Cutis. 2014 Mar;93(3):134-8.

Abstract

The last article in this 5-part series provides a final overview of consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. Optimal management of rosacea requires careful assessment of the patient's clinical features with integration of therapies that adequately treat the presenting signs and symptoms. The treatment consensus recommendations from the AARS are based on 2 major common clinical presentations of rosacea: (1) centrofacial erythema with papulopustular lesions, and (2) centrofacial erythema without papulopustular lesions. The recommendations provided here serve to guide clinicians in their clinical practice.

Publication types

  • Practice Guideline

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Adrenergic alpha-2 Receptor Agonists / therapeutic use*
  • Anti-Infective Agents / therapeutic use*
  • Brimonidine Tartrate
  • Consensus
  • Dermatologic Agents / therapeutic use*
  • Dicarboxylic Acids / therapeutic use
  • Doxycycline / therapeutic use
  • Erythema / drug therapy*
  • Erythema / etiology
  • Humans
  • Metronidazole / therapeutic use
  • Quinoxalines / therapeutic use
  • Rosacea / complications
  • Rosacea / drug therapy*
  • Severity of Illness Index
  • Societies, Medical

Substances

  • Adrenergic alpha-2 Receptor Agonists
  • Anti-Infective Agents
  • Dermatologic Agents
  • Dicarboxylic Acids
  • Quinoxalines
  • Metronidazole
  • Brimonidine Tartrate
  • azelaic acid
  • Doxycycline